-

Lyndra Therapeutics Presents Promising Phase 2 Data on Once-Weekly Oral Risperidone Treatment, LYN-005, in Development for Schizophrenia

Data demonstrate LYN-005 quickly reaches therapeutic levels in patients, provides sustained risperidone drug levels for repeat one-week dosing intervals and reduces peak drug exposure

Lyndra plans to meet with the U.S. Food and Drug Administration to discuss clinical path and pivotal clinical trial design

Investigational product in development has potential to improve compliance and adherence for people with schizophrenia or schizoaffective disorder

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics, a clinical-stage biotechnology company working to make daily pills a thing of the past, today announced results from its Phase 2 study of LYN-005, the Company’s oral, ultra-long-acting, extended-release (ER) risperidone capsule, in development for the weekly treatment of schizophrenia. These data, from the Company’s first repeat dose Phase 2 study in patients, demonstrate that LYN-005 provided sustained therapeutic levels of risperidone over the one-week dosing intervals and reduced peak drug exposure relative to immediate release (IR) risperidone.

Results from the clinical trial will be presented in an oral presentation at the 2021 Congress of the Schizophrenia International Research Society (SIRS), today, Sunday, April 18, 2021.

“Of the 2.2 million people suffering from schizophrenia in the U.S., approximately 50% of those receiving treatment may be non-adherent within the first year of treatment, and a majority will relapse within the first five years of receiving that treatment. Preventing relapse is important in reducing overall healthcare costs and in preserving functioning in individuals with schizophrenia,” said Dr. David Walling, chief clinical officer at Apex Innovative Sciences, chief executive officer and principal investigator of CNS Research and study presenter at SIRS. "These data are very promising as, in addition to improving adherence, weekly oral risperidone treatment may provide more consistent plasma drug levels than daily dosing.”

“These data, along with additional safety data from more than 200 administrations of the Lyndra ER capsule from 10 studies, add to our momentum as we move down the development pathway with plans to conduct our end of Phase 2 meeting with the FDA this summer and initiate a pivotal study of LYN-005 in schizophrenia in the second half of this year,” said Dr. Richard Scranton, chief medical officer of Lyndra Therapeutics. “We look forward to demonstrating the unique clinical value a novel treatment option like LYN-005 could have for people with schizophrenia or schizoaffective disorder as we work to reinforce the broad potential of Lyndra’s breakthrough oral medication platform to address medication non-adherence across a variety of important disease areas.”

About LYN-005 Phase 2 Study

The Phase 2 multiple-dose, randomized, parallel group, placebo-controlled study assessed the safety, tolerability and pharmacokinetics of Lyndra’s ER risperidone capsule in 32 clinically stable patients with a primary diagnosis of schizophrenia or schizoaffective disorder. Although treatment assignment was blinded, the dose level was not blinded. The study included a lead-in period in which patients received IR risperidone tablets (2 mg or 4 mg) for 13 days in order to achieve a steady therapeutic state. Following the lead-in, patients were randomized 3:1 to receive weekly Lyndra ER risperidone capsules (14 mg or 28 mg) with daily IR risperidone-matched placebo or daily IR risperidone (2 mg or 4 mg) with weekly ER risperidone matched placebo for three weeks. The primary endpoints were incidence of treatment emergent adverse events and plasma concentrations of active moiety after repeat doses of LYN-005, relative to IR risperidone.

About Schizophrenia

Schizophrenia is a complex and chronic brain disorder that can be severe and disabling. It affects approximately 2.2 million U.S. adults, often beginning in the late teens or early twenties. The disease typically manifests as hallucinations, delusions and disorganized thoughts and behavior. Medication non-adherence, the most common risk factor for relapse in patients with schizophrenia, can be improved with the use of longer acting formulations of antipsychotic drugs.

About Lyndra Therapeutics

Lyndra Therapeutics is pioneering the first-ever oral, ultra-long-acting, sustained release therapies, which have the potential to fundamentally change the way people take medicine by enabling patients to take a pill once a week rather than daily. The Company’s breakthrough Extended-Release Oral Capsule is designed to provide consistent drug levels for an entire week or as long as a month, from one, normal-sized capsule – something no oral therapy has ever achieved before. Lyndra’s robust pipeline is made up of therapies with established and well-known safety profiles across a number of disease areas in which non-adherence is known to be a significant driver of outcomes, including schizophrenia and other central nervous system diseases, diabetes, cardiovascular disease and opioid abuse disorder, among others. The Company is also committed to advancing its platform across new chemical entities and a variety of critical global and public health opportunities alongside partners such as the Bill & Melinda Gates Foundation and the NIH. For more information, visit the Company’s website at www.lyndra.com.

Contacts

Media
Cammy Duong
Westwicke, an ICR company
cammy.duong@westwicke.com
203-682-8380

Investors
Christopher Brinzey
Westwicke, an ICR company
chris.brinzey@westwicke.com
339-970-2843

Lyndra Therapeutics


Release Versions

Contacts

Media
Cammy Duong
Westwicke, an ICR company
cammy.duong@westwicke.com
203-682-8380

Investors
Christopher Brinzey
Westwicke, an ICR company
chris.brinzey@westwicke.com
339-970-2843

More News From Lyndra Therapeutics

Lyndra Therapeutics Advances Leadership in Key Roles

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics, a clinical-stage biotechnology company working to make daily pills a thing of the past, today announced the appointment of two new members of its Board of Directors: Doug Dachille, former Chief Investment Officer of American International Group, Inc. (AIG), who will also chair the audit committee, and Jillian Moo-Young, Managing Director at AIG. In addition, Lyndra announced the promotion of Jessica Ballinger to President and Chief Operati...

Lyndra Therapeutics’ Investigational Oral, Weekly Opioid Use Disorder Treatment LYN-014 Granted Fast Track Designation by FDA

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics, a clinical-stage biotechnology company working to make daily pills a thing of the past, today announced that LYN-014, the company’s oral, ultra-long-acting, extended-release levomethadone capsule in development for the weekly treatment of opioid use disorder (OUD), has received Fast Track designation (FTD) from the U.S. Food and Drug Administration (FDA). “LYN-014 is an oral, weekly capsule of levomethadone – a medication not yet available...

Lyndra Therapeutics Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Lyndra’s Weekly Risperidone (LYN-005) for the Treatment of Adults with Schizophrenia and Other Indications

WATERTOWN, Mass.--(BUSINESS WIRE)--Lyndra Therapeutics, a clinical-stage biotechnology company working to make daily pills a thing of the past, today announced the positive outcome of an end-of-phase 2 (EOP2) meeting with the U.S. Food and Drug Administration (FDA) providing a clear path to approval for Lyndra’s Weekly Risperidone (LYN-005), the company’s lead product candidate for once-weekly treatment of schizophrenia. The company plans to initiate its pivotal program for LYN-005, designed as...
Back to Newsroom